Increased platelet activation in young Zucker rats with impaired glucose tolerance is improved by acarbose

Summary

Patients with diabetes display increased platelet activation. Recent data show a markedly increased risk for cardiovascular events already in pre-diabetic individuals with impaired glucose tolerance (IGT). We investigated whether IGT is associated with platelet activation. Blood samples were collected from young lean (control) and obese Zucker rats, an established model of IGT, after single oral application of sucrose (4g·kg-1). Platelet-bound fibrinogen and platelet surface-expression of P-selectin were assessed as indices of platelet activation using flow cytometry. In lean Zucker rats, acute sucrose application induced fibrinogen-binding and P-selectin surface-expression, which was prevented by co-administration of acarbose (10mg·kg-1). In obese Zucker rats, platelet activation was already maximally increased under baseline conditions with no significant increase after sucrose application. Chronic treatment with acarbose (15mg·kg-1·day-1) significantly reduced platelet activation in these animals. Acute ingestion of sucrose induces platelet activation which is prevented by acarbose. IGT is associated with marked platelet activation that can be reduced by chronic administration of acarbose.The positive modulation of platelet activation by acarbose may contribute to the reduction of cardiovascular events in patients with IGT.

Keywords

Platelet activation markers - diabetes / metabolic disorders - animal models

^* Both authors contributed equally to this work

• References

• 1 Winocour PD. Platelet abnormalities in diabetes mellitus. Diabetes 1992; 41 (Suppl. 02) 26-31.
• 2 Tschoepe D, Roesen P, Schwippert B. et al. Platelets in diabetes: the role in the hemostatic regulation in atherosclerosis. Semin Thromb Hemost 1993; 19: 122-8.
• 3 Kaplar M, Kappelmayer J, Veszpremi A. et al. The possible association of in vivo leukocyteplatelet heterophilic aggregate formation and the development of diabetic angiopathy. Platelets 2001; 12: 419-22.
• 4 Knobler H, Savion N, Shenkman B. et al. Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Thromb Res 1998; 90: 181-90.
• 5 Graff J, Klinkhardt U, Schini-Kerth VB. et al. Close relationship between the platelet activation marker CD62 and the granular release of platelet-derived growth factor. J Pharmacol Exp Ther 2002; 300: 952-7.
• 6 Glassman AB. Platelet abnormalities in diabetes mellitus. Ann Clin Lab Sci 1993; 23: 47-50.
• 7 Ouvina SM, La RDGreca, Zanaro NL. et al. Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients. Thromb Res 2001; 102: 107-14.
• 8 Shechter M, Merz CN, Paul-Labrador MJ. et al. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol 2000; 35: 300-7.
• 9 Tschoepe D, Driesch E, Schwippert B. et al. Activated platelets in subjects at increased risk of IDDM. DENIS Study Group. Deutsche Nikotinamid Interventionsstudie. Diabetologia 1997; 40: 573-7.
• 10 Despres JP, Lamarche B, Mauriege P. et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-8.
• 11 Pyorala M, Miettinen H, Halonen P. et al. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men : The 22-year follow-up results of the Helsinki policemen study. Arterioscler Thromb Vasc Biol 2000; 20: 538-44.
• 12 Tominaga M, Eguchi H, Manaka H. et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22: 920-4.
• 13 The DECODE study group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 1999; 354: 617-21.
• 14 Chiasson JL, Josse RG, Gomis R. et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-7.
• 15 Chiasson JL, Josse RG, Gomis R. et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOPNIDDM trial. JAMA 2003; 290: 486-94.
• 16 Picard F, Deshaies Y. Postprandial serum lipids and tissue lipoprotein lipase are acutely altered in rats by the α-glucosidase inhibitor acarbose. Horm Metab Res 1996; 28: 377-80.
• 17 Vallejo S, Angulo J, Peiro C. et al. Treatment with acarbose may improve endothelial dysfunction in streptozotocin-induced diabetic rats. J Cardiovasc Pharmacol 2000; 36: 255-62.
• 18 Hauser W, Knobeloch KP, Eigenthaler M. et al. Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. Proc Natl Acad Sci U S A 1999; 96: 8120-5.
• 19 Schwarz UR, Geiger J, Walter U. et al. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets. Thromb Haemost 1999; 82: 1145-52.
• 20 Haller H. The clinical importance of postprandial glucose. Diab Res Clin Pract 1998; 40: 43-9.
• 21 Yamagishi SI, Edelstein D, Du XL. et al. Hyperglycemia potentiates collagen-induced platelet activation through mitochondrial superoxide overproduction. Diabetes 2001; 50: 1491-4.
• 22 Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol 2001; 280: H1480-H1489.
• 23 Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol 2003; 92: 1362-5.
• 24 Gresele P, Guglielmini G, De Angelis M. et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003; 41: 1013-20.
• 25 Westerbacka J, Yki-Jarvinen H, Turpeinen A. et al. Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol 2002; 22: 167-72.
• 26 Hu H, Li N, Ekberg K. et al. Insulin, but not proinsulin C-peptide, enhances platelet fibrinogen binding in vitro in Type 1 diabetes mellitus patients and healthy subjects. Thromb Res 2002; 106: 91-95.
• 27 Winocour PD. Platelets, vascular disease, and diabetes mellitus. Can J Physiol Pharmacol 1994; 72: 295-303.
• 28 Sagcan A, Nalbantgil S, Omay SB. et al. The effect of type II diabetes mellitus on platelet aggregation in patients who underwent percutaneous transluminal coronary angioplasty. Coron Artery Dis 2002; 13: 45-8.
• 29 Hawiger J. Mechanisms involved in platelet vessel wall interaction. Thromb Haemost 1995; 74: 369-72.
• 30 Bhatt DL, Marso SP, Lincoff AM. et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000; 35: 922-8.
• 31 Chiasson JL, Josse RG, Leiter LA. et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996; 19: 1190-3.
• 32 Schwarz UR, Kobsar AL, Koksch M. et al. Inhibition of agonist-induced p42 and p38 mitogen-activated protein kinase phosphorylation and CD40 ligand/P-selectin expression by cyclic nucleotide-regulated pathways in human platelets. Biochem Pharmacol 2000; 60: 1399-407.
• 33 Furie B, Furie BC, Flaumenhaft R. A journey with platelet P-selectin: the molecular basis of granule secretion, signalling and cell adhesion. Thromb Haemost 2001; 86: 214-21.
• 34 Li N, Hu H, Lindqvist M. et al. Platelet-leukocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol 2000; 20: 2702-8.
• 35 Hangaishi M, Taguchi J, Miyata T. et al. Increased aggregation of human platelets produced by advanced glycation end products in vitro. Biochem Biophys Res Commun 1998; 248: 285-92.
• 36 Caimi G, Lo PR, Montana M. et al. Membrane fluidity, membrane lipid pattern, and cytosolic Ca2+ content in platelets from a group of type II diabetic patients with macrovascular complications. Diabetes Care 1995; 18: 60-63.
• 37 Watala C, Boncer M, Golanski J. et al. Platelet membrane lipid fluidity and intraplatelet calcium mobilization in type 2 diabetes mellitus. Eur J Haematol 1998; 61: 319-26.